1. The acute haemodynamic and hormonal effects of 100 mg of captopril (SQ 14.225) orally were tested in twelve healthy men in the sodium replete state before and after indomethacin pretreatment.
Introduction
An orally active inhibitor of angiotensinconverting enzyme, captopril (SQ 14.225), has recently been developed [ 11. Angiotensin-converting enzyme, a peptidyldipeptide hydrolase (EC 3.4.15.1), removes a dipeptide from the decapeptide angiotensin I (ANG I) to produce the potent vasoactive octapeptide angiotensin I1 (ANG 11). Angiotensinconverting enzyme is identical with kininase 11, which inactivates the vasodepressor nonapeptide bradykinin.
The importance of the drug as a therapeutic tool for the management of essential hypertension 121, severe treatment-resistant hypertension [31 and heart failure 141 has now been widely accepted. Inhibition of ANG I1 formation is probably the major mechanism by which captopril reduces blood pressure [51. However, since captopril lowers blood pressure also in states not associated with high ANG I1 levels 161 and in anephric animals and man [7, 81, other mechanisms may be involved 19, 101. Like ANG 11, bradykinin stimulates membrane phospholipase A, in various tissues and thereby the production of vasoactive compounds of the prostaglandin (PG) cascade 111. Recently published data suggest the participation of PGs in the renin-stimulating 1121 and vascular effects of captoprilIl31.
The aim of the present study was to evaluate further the significance of the PG system in the haemodynamic and hormonal effects of captopril in man. In normotensive sodium-replete subjects we could demonstrate that the acute blood pressure lowering and renin stimulating effects of captopril were significantly reduced after effective inhibition of PG formation by indomethacin.
Methods

Protocol
Twelve healthy male volunteers aged 26 to 42 years (mean 33 k 2 SEM) were investigated under active orthostasis and ad lib diet from 08.00 to 12.00 hours. All subjects were fully informed of the experimental nature and the potential risks of the new drug, and written informed consent was obtained. Blood pressure (random zero sphygmomanometer) and heart rate were recorded twice in the sitting position (2 min rest) at 60 rnin, 30 min and immediately before and 30, 60 and 90 min after the oral ingestion of 100 mg of captopril. Excretion of aldosterone, PGE,, sodium and potassium was measured in the urine samples collected for 90 min before and for 90 min after captopril. Urinary sodium excretion was determined in the 24 h period preceding the study. Venous blood was drawn for the determination of plasma renin activity (PRA), ANG I concentration, plasma aldosterone and 18-hydroxycorticosterone (18-OH-B) 60 min and immediately before, and at 30 and 90 min after, captopril. The same protocol was performed again 14 days later under PG blockade with 200 mg of indomethacin (50 mg, respectively, at 01.00, 06.00, 08.00 and at 09.30 hours together with captopril).
A nalytical methods
Sodium and potassium were determined by standard methods. PRA and ANG I were measured by radioimmunoassay (RIA) 1141. Plasma aldosterone and 18-OH-B were determined by RIA with preceding paper chromatography as described elsewhere (151. Urinary aldosterone 18-glucuronide excretion was measured by RIA without preceding chromatography 1161, and PGE, excretion by RIA after silicic acid column chromatography 1 171.
Statistical analysis
Values are means k SEM. The evaluation of the difference between values was performed by variance analysis. When a significant F-value was obtained, single comparisons were made by I-test analyses. Linear regression analyses were performed with data demonstrated in Fig. 2 .
Results
Response to captopril without indomethacin pretreatment
Heart rate before captopril application was 74 2, 76 5 2, and 75 f 2 min-' and remained constant after captopril. Mean arterial blood pressure fell continuously from a control value of about 96 mmHg to a minimum of about 88 mmHg 60 min after captopril and then started to increase again (Fig. 1 ). (1) P < 0.02 and (2) P < 0.05 vs without indomethacin: (a) P < 0405, (b) P < 0.02 and (c) P < 0.05 vs respective control level.
Control
PRA increased continuously from a basal value of 2.6 f 0-4 before to 9.7 f 2.0 ng of ANG I.ml-I h-I at 90 min after captopril. Plasma ANG I concentration paralleled PRA: basal 80 k 9 pg/ml and 300 f 75 90 min after captopril. A significant, positive correlation was obtained by plotting log of PRA level before captopril vs the maximum decrease of mean arterial blood pressure after captopril ( r = 0.72: n = 12: P < 0.01) (Fig. 2) . Plasma aldosterone fell from basal 192 f 12 to 143 f 1 1 pg/ml 90 rnin after captopril (Fig. 1) 
Response to captopril under indomethacin pretreatment
Indomethacin reduced urinary PGE, excretion (to 72 + 1 1 pg/min, P < 0.005). No further change of PGE, excretion was observed after captopril (80 f 1 1 pg/min) ( Table 1) . Heart rate was significantly (P < 0.05) and constantly lower than without indomethacin pretreatment. Baseline blood pressure on indomethacin was unchanged compared with the control, but fell significantly less after captopril than without indomethacin pretreatment (P < 0.05) (Fig. 1) .
Under indomethacin, basal PRA (1.2 f 0.2) as well as the increase of PRA after captopril (to a maximum of 3.0 f 0.5 ng of ANG 1. m1-I. h-l) were significantly reduced (P < 0.05). Baseline ANG I was 60 f 9 and increased only to 160 f 39 pg/ml 90 min after captopril (n.s. and P < 0.05 vs without indomethacin). No correlation between baseline log PRA before captopril and the maximum decrease of blood pressure after captopril could be demonstrated under indomethacin pretreatment (r = -0.40, n = 12; P > 0.05) (Fig, 2) .
Control plasma aldosterone (140 f 12 pg/ml) was decreased under indomethacin (P < 0.01) and remained unchanged after captopril (Fig. 1 ) .
Similarly to plasma values, baseline aldosterone excretion (6.4 f 0.6) was significantly reduced by indomethacin (P < 0.002) and no further decrease occurred after captopril (7.4 f 1.7 ng/min). The preceding 24 h urinary sodium excretion was comparable with that for the 24 h period without indomethacin (188 f 21 mmol). Also, sodium and potassium excretion rates at 90 min before and 90 rnin after captopril remained unchanged, and were similar with and without indomethacin pretreatment (Table 1) . 
Discussion
Captopril reduced blood pressure significantly less in normotensive sodium-replete subjects after pretreatment with indomethacin. Baseline blood pressure under indomethacin was not different, but heart rate was significantly lower both before and after captopril. Indomethacin, in the dose given, was an effective inhibitor of PG biosynthesis, as demonstrated by the decrease of urinary PGE, excretion by about 70%. Inhibition of PG formation reduces the vasodilating capacity of the vasculature, and therefore induces an increase in peripheral vascular resistance [ 181. A compensatory reduction of heart rate may have prevented both an increase of basal blood pressure under indomethacin and a more marked difference in the blood pressure lowering effect of captopril. Alternatively, indomethacin may have reduced heart rate and increased vascular resistance by decreasing vasodilating padrenoreceptors, which mode of action has previously been suggested 1191.
In two recent studies, rapid and short-lasting elevations of either immunoreactive PGE, I131 or of 13,14-dihydro-15-oxo-PGE2 1201 in plasma have been reported after captopril, whereas in one of those studies, plasma 6-0x0-PGF,,. the stable hydrolysis product of prostacyclin, remained unchanged after captopril [201. In another study, however, the possible contribution of an increase of prostacyclin to the effects of captopril was discussed 12 11. Thus the specific action of captopril on the PG system is unknown. Failure of urinary PGE, excretion to increase after captopril has also been observed in a previous study 1221 and may be due to the fact that changes in urinary PG excretion do not necessarily reflect transient changes of vascular PG biosynthesis.
Renin release is controlled by intrarenal PG production [23, 241, and stimulated PG formation may contribute to the increase of PRA after captopril I 12, 2 11. Therefore the significant reduction by indomethacin of both baseline PRA before and stimulated PRA after captopril is most likely to be due to the effective inhibition of PG formation (Fig. 1) . Furthermore, the significant positive relationship between precaptopril PRA and the captopril-induced fall in blood pressure observed in subjects not pretreated with indomethacin was abolished under indomethacin pretreatment (Fig. 2) . The disappearance of the positive correlation between pre-captopril PRA and post-captopril fall in blood pressure after indomethacin pretreatment suggests that indomethacin interferes with mechanism(s), probably prostaglandin synthesis. involved in the blood pressure lowering and renin stimulating effects of captopril.
Captopril induced a sustained fall in plasma aldosterone, aldosterone excretion and plasma 18-OH-B without indomethacin pretreatment. The effective decrease of ANG I1 formation by captopril is most probably the reason for the fall of the mineralocorticoid levels. Our results support the hypothesis that ANG I1 is a dominant stimulator even for 18-OH-B secretion [251. Under indomethacin, basal aldosterone and 18-OH-B production was significantly reduced. This could be the result of both the inhibition of PG-mediated baseline renin secretion and hence reduced ANG I1 production, and the consequence of decreased adrenal PG formation, since these are possibly involved in the secretion of these mineralocorticoids 1261. The absence of a further decrease of aldosterone and the smaller reduction of 18-OH-B levels after captopril could then be due to their already diminished basal release as a result of indomethacin pretreatment.
